| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Haralampos Moutsopoulos | Q87896552 |
| P2093 | author name string | Clio P Mavragani | |
| P2860 | cites work | Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome | Q33372523 |
| Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects | Q33386179 | ||
| Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity | Q33479779 | ||
| Obstetric and gynaecological profile in patients with primary Sjögren's syndrome | Q33566611 | ||
| The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome | Q33566683 | ||
| Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome | Q33592784 | ||
| American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort | Q34260251 | ||
| Endocrine alterations in primary Sjogren's syndrome: an overview. | Q34281232 | ||
| Clinical manifestations and early diagnosis of Sjögren syndrome | Q34330087 | ||
| Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group | Q34523084 | ||
| Estimation of the prevalence of primary Sjögren's syndrome in two age-different community-based populations using two sets of classification criteria: the Hordaland Health Study | Q34735010 | ||
| The geoepidemiology of Sjögren's syndrome | Q35012205 | ||
| Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome | Q35082778 | ||
| Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome | Q35307717 | ||
| Prevalence of Sjögren's syndrome in a closed rural community | Q35547455 | ||
| Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren's syndrome. | Q53892066 | ||
| Methotrexate in primary Sjögren's syndrome. | Q53982565 | ||
| Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. | Q55033876 | ||
| Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. | Q55055463 | ||
| Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients | Q56453023 | ||
| Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry | Q57612819 | ||
| Raynaud's phenomenon in primary Sjögren's syndrome | Q58479951 | ||
| Nephrocalcinosis in Sjögren's syndrome: a late sequela of renal tubular acidosis | Q67932655 | ||
| Vasculitis in primary Sjögren's syndrome. Histologic classification and clinical presentation | Q69104764 | ||
| Anti-La (SS-B): a diagnostic criterion for Sjögren's syndrome? | Q69637470 | ||
| Hand radiographic changes in patients with primary and secondary Sjögren's syndrome | Q69706226 | ||
| Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren's syndrome | Q71792667 | ||
| Liver involvement in primary Sjögren's syndrome | Q72117463 | ||
| Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome | Q74167311 | ||
| Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee | Q77386006 | ||
| Antiovarian antibodies in primary Sjogren's syndrome | Q80413779 | ||
| Stress, coping strategies and social support in patients with primary Sjögren's syndrome prior to disease onset: a retrospective case-control study | Q80706167 | ||
| Sjögren's Syndrome | Q80975819 | ||
| Assessment of fatigue in primary Sjögren's syndrome: the Swedish version of the Profile of Fatigue | Q82175469 | ||
| Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome | Q82777758 | ||
| Peripheral neuropathies in Sjogren syndrome: a new reappraisal | Q82966736 | ||
| Increased prevalence of antibodies to thyroid peroxidase in dry eyes and mouth syndrome or sicca asthenia polyalgia syndrome | Q84236530 | ||
| IgG4 multiorgan lymphoproliferative syndrome as a differential diagnosis of primary Sjogren's syndrome in men? | Q84287326 | ||
| Psychopathological and personality features in primary Sjogren's syndrome--associations with autoantibodies to neuropeptides | Q84357788 | ||
| Brief report: adrenal autoimmunity in primary Sjögren's syndrome | Q84898393 | ||
| Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease | Q35548191 | ||
| Central nervous system involvement in Sjogren's syndrome | Q35554134 | ||
| Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye | Q35589451 | ||
| Clinical and pathological roles of Ro/SSA autoantibody system. | Q36469094 | ||
| The management of Sjögren's syndrome | Q36577478 | ||
| Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry | Q36677386 | ||
| Conventional therapy of Sjogren's syndrome | Q36997278 | ||
| Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren's syndrome. | Q37246044 | ||
| Renal involvement in primary Sjögren's syndrome: a clinicopathologic study | Q37330297 | ||
| Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept | Q37331753 | ||
| Primary Sjogren's syndrome: too dry and too tired | Q37690497 | ||
| Autoimmune response and target autoantigens in Sjogren's syndrome. | Q37772540 | ||
| Treatment of primary Sjögren syndrome: a systematic review | Q37776086 | ||
| Pathogenesis of Sjögren's syndrome and therapeutic consequences | Q37776624 | ||
| Prevalence and predictors of Sjogren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. | Q38045765 | ||
| Anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome | Q38058469 | ||
| Elevated IgG4 serum levels among primary Sjögren's syndrome patients: do they unmask underlying IgG4-related disease? | Q39147898 | ||
| Raynaud's phenomenon in primary Sjögren's syndrome. | Q39268837 | ||
| Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial | Q39380859 | ||
| A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome | Q39403809 | ||
| Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. | Q39599564 | ||
| Immune complex glomerulonephritis in sicca syndrome | Q39854606 | ||
| Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary Sjögren's syndrome? | Q39889684 | ||
| Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome | Q40650085 | ||
| Neurologic disease in Sjögren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis | Q40792866 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. | Q41930645 | ||
| Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). | Q42459992 | ||
| Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome | Q43432949 | ||
| Corneal melt as the initial presentation of primary Sjögren's syndrome. | Q43541184 | ||
| Topical nonsteroidal agents and corneal wound healing | Q43721502 | ||
| Prevalence of primary Sjögren's syndrome in an elderly population | Q44356526 | ||
| Impaired functional status in primary Sjögren's syndrome | Q44473952 | ||
| Topical and systemic medications for the treatment of primary Sjögren's syndrome. | Q44498935 | ||
| The co-occurrence of Hashimoto thyroiditis in primary Sjogren's syndrome defines a subset of patients with milder clinical phenotype | Q45348203 | ||
| Sleep disturbances in patients with primary Sjögren's syndrome | Q48857555 | ||
| Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial | Q50566871 | ||
| Personality structure disturbances and psychiatric manifestations in primary Sjögren's syndrome. | Q51175143 | ||
| Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. | Q51412493 | ||
| Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. | Q51893824 | ||
| Labial salivary gland biopsies in Sjögren's syndrome: still the gold standard? | Q53040735 | ||
| MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. | Q53548061 | ||
| P433 | issue | 15 | |
| P304 | page(s) | E579-86 | |
| P577 | publication date | 2014-02-24 | |
| P1433 | published in | Canadian Medical Association Journal | Q5030320 |
| P1476 | title | Sjögren syndrome | |
| P478 | volume | 186 |
| Q52336160 | Aberrant cell signalling in PBMCs upon IFN-α stimulation in primary Sjögren's syndrome patients associates with type I interferon signature. |
| Q52645247 | Behcet disease combined with Sjogren syndrome: A unique case report and literature review. |
| Q26778403 | Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis |
| Q60921009 | Correlation between Xerostomia index, Clinical Oral Dryness Scale, and ESSPRI with different hyposalivation tests |
| Q39177903 | Extrahepatic Manifestations of Primary Biliary Cholangitis |
| Q90316133 | Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients |
| Q57824160 | Hypokalemic Paralysis Secondary to Renal Tubular Acidosis Revealing Underlying Sjogren's Syndrome |
| Q64275957 | MIST1, an Inductive Signal for Salivary Amylase in Mesenchymal Stem Cells |
| Q41259985 | MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome |
| Q40540065 | Metabolic syndrome in Sjögren's syndrome patients: a relevant concern for clinical monitoring |
| Q35587450 | Mouse Models of Primary Sjogren's Syndrome |
| Q50108711 | Neonatal Systemic Lupus Erythematosus Syndrome: a Comprehensive Review |
| Q49343933 | P2Y2 R Deletion Ameliorates Sialadenitis in IL-14α-transgenic Mice. |
| Q48562698 | Patient reported outcome and experience measures of oral disease in oral medicine. |
| Q37205067 | Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. |
| Q37745058 | Rapidly Developed Multiple Face and Neck Skin Cancers in a Patient with Sjögren's Syndrome: A Case Report. |
| Q59136355 | Recurrent Cerebral Infarctions in Primary Sjögren Syndrome: A Case Report and Literature Review |
| Q37621925 | Sex differential association of dermatomyositis with Sjögren syndrome |
| Q64118858 | Single Cell Based Phosphorylation Profiling Identifies Alterations in Toll-Like Receptor 7 and 9 Signaling in Patients With Primary Sjögren's Syndrome |
| Q41991901 | Single-cell analysis reveals sexually dimorphic repertoires of Interferon-γ and IL-17A producing T cells in salivary glands of Sjögren's syndrome mice |
| Q90415487 | Study of the incidence of osteoporosis in patients with Sjögren's syndrome (pSS) and investigation of activation of the RANKL /RANK and osteoprotegerin (OPG) system |
| Q60948114 | TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients |
| Q98735476 | The Effects of Androgens on T Cells: Clues to Female Predominance in Autoimmune Liver Diseases? |
| Q47161206 | The risk of nontuberculous mycobacterial infection in patients with Sjögren's syndrome: a nationwide, population-based cohort study |
| Q36042432 | Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis |
| Q54231118 | Unique glandular ex-vivo Th1 and Th17 receptor motifs in Sjögren's syndrome patients using single-cell analysis. |
Search more.